Cassava Sciences Inc vs Verizon Communications Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Verizon Communications Inc trades at $47.02 (market cap $196.40B). The key difference: Verizon Communications Inc is far larger — about 4113.1× Cassava Sciences Inc's market cap, and Verizon Communications Inc pays a 5.99% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | VZ | |
|---|---|---|
Market Cap | $47.75M | $196.40B |
Sector | Health | Media |
52-Week High | $4.64 | $51.38 |
52-Week Low | $0.87 | $38.40 |
Enterprise Value | -$34.93M | $383.10B |
Volume | — | 22,584,735 |
Dividend Yield | — | 5.99% |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Verizon (VZ) trades at $47.03, down 0.06% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $49.69. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.30 surpassing the $1.27 estimate. The company maintains strong cash flow from operations at $37.14 billion in 2025 and a healthy dividend yield, supported by a $0.71 per share payout scheduled for August 2026.
VZ presents a value opportunity with a low P/E of 12.31 and stable revenue around $138 billion, though competitive pressures from new entrants like SpaceX's Starlink and high debt levels pose risks. Analyst sentiment is mixed with 36.7% buy ratings, but fundamentals suggest resilience for income-focused investors seeking telecom exposure.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →